- Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder
- The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment
- Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of neurological conditions
- The patent application bolsters Odyssey’s growing list of medical devices, which currently comprise a CardioMap, a heart monitoring and screening device, as well as Save-A-Life, a handheld choking rescue device
Odyssey Health (OTC: ODYY), a medical enterprise focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced filing for the United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device. This comes on the heels of the successful completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial, which saw the successful use of the device, and a proven safety profile of the company’s concussion pharmaceutical treatment.
“Following the completion of this Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment,” noted Michael Redmond, Odyssey’s…
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
